Lumos Diagnostics (ASX:LDX)
ASX announcement history & article coverage
Transparent by design.
Announcments by Lumos Diagnostics (ASX:LDX) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Closure of A$5M Loan Facility with Major Shareholders
Lumos Receives Research & Development Tax Rebate
Lumos Diagnostics Receives A$709,837 R&D Tax Rebate for FY25
Change of Director's Interest Notice - SL
Application for quotation of securities - LDX
Change of Director's Interest Notice - CR
Investor Presentation - FebriDx US Commercial Update
Change of Director's Interest Notice - DW
FebriDx US Commercial Update Webinar Invitation
Application for quotation of securities - LDX
Section 708A Cleansing Statement
FebriDx U.S. Rollout and Reimbursement Update - Amended
Lumos Diagnostics reports positive early U.S. rollout and reimbursement progress for FebriDx® ahead of 2026/27 flu season
FebriDx U.S. Rollout and Reimbursement Update
Lumos reports positive early U.S. rollout and reimbursement progress for FebriDx test
FebriDx Paediatric Study Enrolment Milestone Achieved
Lumos Diagnostics hits 250 patient enrolment milestone in BARDA-funded FebriDx paediatric study, earning US$670K payment
Lumos receives US$0.5m CLIA waiver milestone payment
Change of Director's Interest Notice - CR
Change of Director's Interest Notice - SL
Notification regarding unquoted securities - LDX
Notification regarding unquoted securities - LDX
Application for quotation of securities - LDX
Results of Share Purchase Plan
Change of Director's Interest Notice - SL
Q3 FY26 Results Investor Presentation
Quarterly Activities/Appendix 4C Cash Flow Report
Lumos Diagnostics secures FDA CLIA waiver for FebriDx®, triggers US$6.2M milestone payments, reports 37% revenue growth in Q3 FY26
Notification of cessation of securities - LDX
Lumos Q3 FY26 Results Webinar Invitation
Lumos expands WellStreet Urgent Care locations
Change in substantial holding from RYD
Lumos receives US$5m FebriDx milestone payment from PHASE